Vivo Capital Fund IX, L.P. 4
4 · Instil Bio, Inc. · Filed Mar 25, 2021
Insider Transaction Report
Form 4Exit
Vivo Capital IX, LLC
10% Owner
Transactions
- Conversion
Common Stock
[F1][F2]2021-03-23+11,709,696→ 11,709,696 total - Conversion
Common Stock
[F1][F2]2021-03-23+477,091→ 12,186,787 total - Purchase
Common Stock
[F2]2021-03-23$20.00/sh+300,000$6,000,000→ 12,486,787 total - Conversion
Series B Preferred Stock
[F1][F2]2021-03-23−9,758,080→ 0 total→ Common Stock (11,709,696 underlying) - Conversion
Series C Preferred Stock
[F1][F2]2021-03-23−397,576→ 0 total→ Common Stock (477,091 underlying)
Footnotes (2)
- [F1]Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date.
- [F2]The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. As the managing members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.